




Information regarding proposed board of directors:

<p>Jan Ståhlberg</p> 	<p>Proposed for re-election as Director and Chairman of the Board</p>
<p>Year of birth</p>	<p>1962</p>
<p>Education/Experience</p>	<p>BSc Business and Economics, Stockholm School of Economics. Studies at the MBA program at New York University, Stern School of Business. Various positions at Ovako Steel during the period 1984-1994, the latest as Chief Financial Officer Various positions and partner in EQT during the period 1995-2018 Board work in the cancer diagnostics company Dako, Carl Zeiss Vision and Gambro among others</p>
<p>Positions in the company</p>	<p>-</p>
<p>Other significant positions</p>	<p>CEO of Trill Impact AB Board member of ITB-Med AB Board member of Trelleborg AB</p>
<p>Holdings of securities in the company</p>	<p>Class B shares: 2 956 831 shares</p>
<p>Independence</p>	<p>Independent in relation to the Company, corporate management and the Company's largest shareholders</p>
<p>Year elected to the Board of Directors</p>	<p>2018</p>

<p>Mia Arnhult</p> 	<p>Proposed for re-election as Director of the Board.</p>
<p>Year of birth</p>	<p>1969</p>
<p>Education/Experience</p>	<p>Degree in business finance and trade law from the University of Lund. Former CFO of Corem Property Group AB and M2 Gruppen. Several years of experience as auditor with Lindebergs Grant Thornton among others</p>
<p>Positions in the company</p>	<p>Director of the Board. Chairman of the Audit Committee</p>
<p>Other significant positions</p>	<p>CEO and Member of the Board of Directors of M2 Asset Management AB (publ), M2 Gruppen AB and M2 Gruppen 1 AB. CEO of Locellus AB and Arnhult Invest AB. Member of the Board of Directors Odd Molly International AB (publ), Devyser Holding AB, Lidingoloppet, Suburban Properties Stockholm AB with subsidiaries and M2 Capital Management AB</p>
<p>Holdings of securities in the company</p>	<p>Class B shares: 50,000 shares (directly) Class B shares: 502,000 shares (through legal entity)</p>
<p>Independence</p>	<p>Independent in relation to the Company, corporate management and the Company's largest shareholders</p>
<p>Year elected to the Board of Directors</p>	<p>2014</p>

<p>Christian Kinch</p> 	<p>Proposed for re-election as Director of the Board.</p>
<p>Year of birth</p>	<p>1966</p>
<p>Education/Experience</p>	<p>Studies at the Stockholm School of Economics. Founder of Kinchard AB and Netpharma AB.</p>
<p>Positions in the company</p>	<p>Director of the Board Group CEO since June 2015 and during 2005 - March 2014. Chairman of the Board of Directors March 2014 – June 2015</p>
<p>Other significant positions</p>	<p>Board member of Swecare AB. Chairman of the Board of Directors of SWIB Holding AB (holding company for Smartwise Sweden AB and Procella Therapeutics AB). Owner and Director of the Board of KK Invest AB, KK Consult AB and KK Technology AB.</p>
<p>Holdings of securities in the company</p>	<p>Class B shares: 100 (family) Class A shares: 2,000,000 (through legal entity) Class B shares: 4,125,877 (through legal entity)</p>
<p>Independence</p>	<p>Not independent in relation to the Company, group management or the Company's largest shareholders</p>
<p>Year elected to the Board of Directors</p>	<p>2011</p>

<p>Anna Martling</p> 	
<p>Year of birth</p>	<p>1969</p>
<p>Education/Experience</p>	<p>M.D, Karolinska Institutet Board Certified Surgeon Ph.D, Karolinska Institutet Professor of Surgery, Karolinska Institutet</p>
<p>Positions in the company</p>	<p>-</p>
<p>Other significant positions</p>	<p>Dean Campus North, Karolinska Institutet Senior Consultant Surgeon, Karolinska University Hospital Research Group Leader, Karolinska Institutet</p> <p>Previous board member of research committee of Stockholm Cancer Society, Swedish Cancer Society and Swedish Research Council.</p> <p>Member of the Board of Research at Karolinska Institutet (2015 - 2018) Member of Board of Research KI/SLL (2016 - 2018) Member of Faculty Board, Karolinska Institutet (2019 -)</p> <p>Various member of boards of KI Cancer, StratCan and CIMED, Karolinska Institutet</p>
<p>Holdings of securities in the company</p>	<p>Class B shares: 823 shares</p>
<p>Independence</p>	<p>Independent in relation to the Company, corporate management and the Company's largest shareholders</p>
<p>Year elected to the Board of Directors</p>	<p>Proposed for election at the Annual General Meeting 2019</p>

<p>Thomas von Koch</p> 	
<p>Year of birth</p>	<p>1966</p>
<p>Education/Experience</p>	<p>Master of Science in Business and Economics from Stockholm School of Economics with two majors, in Financial Economics and Accounting & Finance.</p> <p>CEO and Managing Partner EQT Partners AB from 1 March 2014 – 31 December 2018.</p> <p>Previous board member of:</p> <ul style="list-style-type: none"> EQT AB StjärnTVnätet AB TAC AB Com Hem AB Gambro AB Duni AB IP Only AB
<p>Position in the company</p>	<p>-</p>
<p>Other significant positions</p>	<p>From 1 January 2019 Deputy MD in EQT Partners AB Deputy board member Kochcompany AB Board member TomEnterprise AB</p>
<p>Holdings of securities in the company</p>	<p>Class B shares: 160,395 (directly) Class A shares: 2,000,000 (through legal entity) Class B shares: 3,965,483 (through legal entity)</p>
<p>Independence</p>	<p>Independent in relation to the Company and corporate management. Not independent in relation to the Company's largest shareholders.</p>
<p>Year elected to the Board of Directors</p>	<p>Proposed for election at the Annual General Meeting 2019</p>